Mutation-Adjusted Risk Score (MARS)
Stratifies prognostic risk for adults with advanced systemic mastocytosis.
Advice
- Interpret results alongside the specific disease variant, clinical symptoms, extent of organ dysfunction, and mast cell burden when determining treatment strategies.
- A higher score is associated with poorer prognosis, and these patients may be prioritized for more aggressive management.